NL-OMON48173招募中2 期
Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLC - TATI
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histologically confirmed metastatic NSCLC, characterized by a sensitizing
- •exon 19 deletion or exon 21 L858R EGFR mutation., 2. WHO performance status
- •0-2., 3. Eligible for osimertinib treatment according to the label and
- •according to the treating physician., 4. Patients must be >=18 years of age.
排除标准
- •1. Patients with symptomatic central nervous system metastases who are
- •neurologically unstable. Unstable brain metastases except for those who have
- •completed definitive therapy and have had a stable neurological status for 2
- •weeks after completion of definitive therapy. Patients may be on
- •corticosteroids to control brain metastases if they have been on a stable dose
- •for 2 weeks prior to the start of study treatment and are clinically
- •asymptomatic.
研究者
相似试验
进行中（未招募）
1 期
ctDNA guided treatment of early resistance to targeted treatmentPatients with histologically confirmed metastatic NSCLC, characterized by a sensitizing exon 19 deletion or exon 21 L858R EGFR mutation that are eligible for osimertinib treatment.MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004798-29-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis30
已完成
不适用
ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCarcinoma, Non-Small-Cell LungNCT04148066The Netherlands Cancer Institute104
进行中（未招募）
1 期
A trial using ctDNA mutation tracking to detect cancer cells in the blood of patients with triple negative breast cancer who have completed standard treatmentEarly stage triple negative breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000508-92-GBThe Institute of Cancer Research150
Unknown
不适用
Recurrence Monitoring in NSCLC Using Circulating Tumor DNANon Small Cell Lung CancerNCT03878537Scripps Translational Science Institute50
进行中（未招募）
不适用
A trial using blood tests to detect cancer cells after standard treatment to trigger additional treatment in early stage triple negative breast cancer patientsCancerBreast cancerISRCTN12569958Institute of Cancer Research208